Matt Miessau

Matthew Miessau has been an analyst at Epidarex Capital since 2014. He focuses on conducting due diligence on prospective fund investments as well as sourcing and analyzing opportunities for Epidarex’s strategic investors. Miessau is also an instructor at the National Institutes of Health Foundation for Advanced Education in the Sciences, teaching biomedical business development for scientists. 

Paul Silber

Paul Silber is the founding principal at Blu Venture Investors. He launched and grew the company In Vitro Technologies, Inc. for 15 years before he sold it for $30 million in 2006. He is currently board director or advisor to multiple companies as well as the Biotechnical Institute of Maryland. He also chairs the Greater Baltimore Technology Council’s Biotech Roundtable. Silber holds a Ph.D. in toxicology and is an inventor on five patents.